Top Markets
#1 QuantixAI QuantixAI +105.36%
#2 龙虾 (Lobster) 龙虾 (Lobster) +67.63%
#3 Pons Pons +30.61%
#4 MetaDAO MetaDAO +27.67%
#5 Rain Rain +23.05%
#6 Bedrock Bedrock +21.57%
#7 Ontology Gas Ontology Gas +17.29%
#8 Prom Prom +16.07%
#9 Humanity Humanity +14.61%
#10 Stacks Stacks +14.02%
Coin of the day
QuantixAI QuantixAI
Settings
Language
ENGLISH
Currency
USD
Theme
Theseus Pharmaceuticals, Inc. Theseus Pharmaceuticals, Inc.

Theseus Pharmaceuticals, Inc.

THRX
Rank in Stocks #19949
Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on... Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and bringing to market targeted treatments for cancer patients. Their leading investigational compound, THE-630, is a pan-KIT inhibitor undergoing Phase I clinical trials for treating gastrointestinal stromal tumors. The company is also advancing a fourth-generation EGFR inhibitor specifically designed to combat the C797S EGFR mutation, which confers resistance to initial or later-line osimertinib therapy in individuals with non-small cell lung cancer. All their research and development efforts aim to overcome drug resistance mutations within key driver oncogenes, which are mutated genes that promote cancer. Founded in 2017, the company operates out of Cambridge, Massachusetts.
Share Price
$4.06
Last synced: 2024-02-23
Market Cap
$145.61M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Theseus Pharmaceuticals, Inc. (THRX)

Category

Healthcare
Revenue for Theseus Pharmaceuticals, Inc. (THRX)
Revenue in Aug 2026 TTM: 0
According to Theseus Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Theseus Pharmaceuticals, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH